Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorTAGHY, N.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCAMBON, Linda
dc.contributor.authorCOHEN, J. M.
dc.contributor.authorDUSSART, C.
dc.date.accessioned2021-02-17T15:58:55Z
dc.date.available2021-02-17T15:58:55Z
dc.date.issued2020
dc.identifier.issn1176-6336 (Print)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26285
dc.description.abstractEnIntroduction: The risk of polypharmacy is on the rise in most industrialized countries, threatening to burden their health systems. Although many definitions exist and numerous concepts are found in literature as synonyms, the phenomenon of polypharmacy remains poorly defined. The aim of this literature review is to provide an overview of available definitions of polypharmacy, to analyse their convergences and divergences and to discuss the consequences on the assessment of the problem. Methods: A literature review was conducted to identify all published systematic reviews on definitions of polypharmacy available via Scopus and Pubmed databases. The Assessment of Multiple Systematic Reviews (AMSTAR) tool was used to appraise the methodological quality of the selected reviews. Available definitions and other characteristics were extracted; summarised in a table and analysed. Results: Six systematic reviews were identified. They were published between 2000 and 2018. Three focussed on definitions of polypharmacy in the elderly; two in the general population and one in children. The strategy adopted in reviews is more rigorous in the most recent ones. However, they remain, at best, partially exhaustive. The definitions found in the literature used two main approaches, either (i) quantitative, applying varying thresholds and types of polypharmacy based on the number of medications being taken by the patient (ii) qualitative, based on the clinical indications and effects of a given drug regimen, with a growing number of characteristics to describe polypharmacy. The term “inappropriate” is increasingly associated with polypharmacy especially in studies that aimed to use this definition to identify possible solutions for healthcare providers in the field related to aging. Conclusion: This review confirms a high variability and an evolution in the approaches defining “polypharmacy” in the absence of a consensus following standardized criteria. That makes it very difficult to estimate and measure the outcomes associated with this phenomenon.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subjectMRISP
dc.title.enFailure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts-Results of a Literature Review
dc.title.alternativeTher Clin Risk Managen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.2147/tcrm.S214187en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32103967en_US
bordeaux.journalTherapeutics and Clinical Risk Managementen_US
bordeaux.page57-73en_US
bordeaux.volume16en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamMRISPen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03144568
hal.version1
hal.date.transferred2021-02-17T15:58:59Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Therapeutics%20and%20Clinical%20Risk%20Management&rft.date=2020&rft.volume=16&rft.spage=57-73&rft.epage=57-73&rft.eissn=1176-6336%20(Print)&rft.issn=1176-6336%20(Print)&rft.au=TAGHY,%20N.&CAMBON,%20Linda&COHEN,%20J.%20M.&DUSSART,%20C.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée